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Abstract
Serotonin [5-hydroxy-tryptamine (5-HT)] exerts a number of effects in the mammalian 
heart: increase in heart rate, increase in force of contraction, fibrosis of cardiac valves, 
coronary constriction, arrhythmias and thrombosis. These effects are, in part, mediated 
by 5-HT-receptors, in part, directly by 5-HT action on intracellular proteins. In the begin-
ning, 5-HT was thought to be only produced in the gut and then transported into the 
heart via platelets, because platelets can take up 5-HT in the gut and enter the capillaries 
and thus the mammalian heart. 5-HT is to a large extent metabolized in the liver and 
excreted via the urine. Here, we will also overview data that argue for additional path-
ways, namely production and degradation of 5-HT in the cells of the heart itself.
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1. Introduction
Practically, all physiological systems of the mammalian body have been reported to be affected 
by 5-hydroxy-tryptamine (5-HT). Prominently affected systems are the central nerve system 
and the peripheral nerve system but 5-HT also plays a complex role in the gut, the liver and 
e.g. spleen. However, 5-HT also seems to have profound (patho)-physiological roles in the 
heart. Some drugs that are devised to treat non-cardiac diseases alter the level of 5-HT in the 
heart or act as agonists/antagonists on one or more of the 5-HT-receptors in the mammalian 
heart. Finally, there is evidence that in cardiovascular diseases 5-HT itself can affect the heart 
in a compensatory or detrimental way. Some newer aspects of the action and generation of 
5-HT in the mammalian heart with special emphasis on the human heart will be addressed 
here. Finally, gaps in our knowledge, conflicting views, some challenging hypotheses and 
suggestions for further research will be put forward.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Historical aspects
The history of 5-HT goes back in time. Some write that the first hint of 5-HT’s existence can be 
traced back to the work of Otto Weiss (1896, Göttingen, Germany) [1], who noted that serum 
in contrast to plasma exerted vasoconstrictory responses in dogs, a finding which one could 
now explained by high (serum) and low (plasma) levels of 5-HT in the samples of Weiss [2].
Enterochromaffin cells were first described in the lining of the gastrointestinal tract at the 
end of the nineteenth century (Charkow in ancient Imperial Russia) [3]. Using various stain-
ing reactions, these enterochromaffin cells were found in the gut of many species [4]. Early 
work described an increase in blood pressure in one rabbit with extracts from human carci-
noid tumors (tumors derived from enterochromaffin cells [5]). Stimulated by these findings, 
Vittorio Erspamer in Italy (working in Pavia, Rome and later in Bari, Italy) studied acetone 
extracts of mucosal intestinal strips from animals (mainly rabbits) for decades. In an early 
paper, he presented an original recording for a positive inotropic effect (PIE) of “enteramine” 
(the putative active ingredient of his acetone extract) on the frog heart, conceivably the first 
inotropic effect reported for 5-HT [6]. Later he purified the extract further and reported the 
presence of a putative indolalkylamine that increased force in isolated hearts of various kinds 
of molluscs [7]. His efforts culminated in identifying his “enteramine” as 5-hydroxy-trypt-
amine [8]. 5-HT was, independently from Erspamer, studied by the group of Irvine H. Page in 
the USA (Cleveland, Ohio) and given its current name “serotonin” [9]. The American authors 
were investigating naturally occurring vasoconstrictory compounds (vasoconstriction being 
tested in rabbit ear arteries) in serum of humans in order to find a putative cause of peripheral 
arterial hypertension in humans. As a first step, they partially purified a vasoconstrictory 
compound from clotted serum of beef [10] and later this vasoconstrictor (their “serotonin”) by 
chemical synthesis was identified as 5-hydroxy-tryptamine [11]. Synthetic 5-HT was shown 
in early work to act on blood pressure in animals (cats and rabbits [12]) and hypertensive 
patients [12]. These authors noted in patients an initial fall in blood pressure (measured in 
brachial arteries, absent in the presence of atropine) followed by a modest increase in blood 
pressure (up to 20 mm Hg increase). Patients injected with 5-HT complained of nausea, tight-
ness of the breast, and dizziness, but the pulse rate was not reported [12]. A clear positive 
chronotropic effect (PCE) of 5-HT by venous injection in humans was published some years 
later [13, 14]. Initial attempts using biological tests failed [6] to detect 5-HT in the heart, but 
several decades later, the presence of 5-HT in the mammalian heart (hamster, human heart) 
has been proven (using more sensitive methods (fluorescence): e.g. [15]).
3. Sources of cardiac 5-HT
Ninety percent of 5-HT in the body is present in enterochromaffin cells in the gut, 5% in plate-
lets, and about 2% in brain [16]. 5-HT in the blood is mainly assumed to be synthesized in 
enterochromaffin cells of the gastrointestinal tract [17, 18]. 5-HT is released from these entero-
chromaffin cells and is taken up rapidly by thrombocytes (review: [19, 20]). Alternatively, 
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5-HT enters the portal vein and passes into liver cells where it is rapidly degraded by mono-
amine oxidase-A (MAO-A) (see below) and its metabolites leave the body via the urine. Thus, 
platelets are commonly thought to be the main source of 5-HT that reaches the mammalian 
heart. Many cell types like mast cells also contain 5-HT (see below) and small numbers of 
mast cells are present in the mammalian heart [19]. Many immune cells contain 5-HT and are 
also found in small numbers in the heart. Newer data (using more sensitive analytical meth-
ods: HPLC, GC, MS) cast some doubt on this classical concept (see below). Thus, 5-HT was 
detected not only in hamster heart and human heart [15] but also in mouse heart [21], rat neo-
natal cardiomyocytes [22], and adult mouse cardiomyocytes [23]. The content of 5-HT in the 
hamster heart was reduced by the treatment of the living hamster with pargyline, an inhibitor 
of MAO-A [15] suggesting degradation of 5-HT in the heart via MAO-A. Moreover, the level 
of 5-HT in the hamster heart was not reduced by injecting in the living hamster a dose of 
6-hydroxy-dopamine, sufficiently high to reduce cardiac norepinephrine levels, suggesting 
that cardiac 5-HT is not derived to a measurable extent from the neuronal cells in the hamster 
heart [15]. Compound 48/80, a substance that is known to release 5-HT from cells in other 
organ systems, increased force of contraction in isolated atrial preparation of 5-HT
4
-receptor 
overexpressing mice, indicating that releasable 5-HT is present in these cardiac preparations, 
but leaving open the question of its cellular origin [24].
5-HT is formed from L-tryptophan by the enzyme tryptophan hydroxylase (TPH, see next 
paragraph). Peroral treatment of animals or humans with tryptophan (an essential amino 
acid) increases body concentrations of tryptophan. Uptake of tryptophan in the gut is brought 
about by the protein transporter enzymes SLC6A19 and SLC16A10 [25]. Protein-rich food is 
known to compete with these transporters and will lead to lower levels of tryptophan in the 
body [25]. Effects of 5-HT in the heart were usually thought to be due to 5-HT released from 
intact platelets. Indeed huge amounts of 5-HT can be released from activated thrombi in the 
heart. These thrombi are formed in atrial fibrillation and contain, of course, thrombocytes. 
5-HT released from thrombi may then reach by diffusion endothelial cells. If these endothelial 
cells were lacking (for instance after local injury), 5-HT may act on 5-HT-receptors on the outer 
surface of smooth muscle cells or may reach cardiomyocytes. Conceivably, 5-HT in the plasma 
may reach the heart from the lungs (lung veins, left atrium, and left ventricle) and then enter 
the coronaries and thence affect the whole heart. In addition, 5-HT in the plasma may come 
from the periphery (via the right atrium and right ventricle) and exert right heart sided effects. 
Indeed, in tumors producing 5-HT (carcinoids, see below), such pathways are accepted to 
occur. Depending on the anatomic localization of the tumor, vasoconstriction would occur 
and should explain cases of left or right (or global) hypertrophy or contractile failure of the 
heart [26]. Furthermore, the 5-HT producing enzyme TPH1 (see below) was detected in pul-
monary endothelial cells and could therefore generate 5-HT in the lung and it is conceivable 
that this 5-HT of pulmonary origin reaches the left heart via the pulmonary veins [27]:
There is precedence in the literature that a neurotransmitter like 5-HT can be formed in the 
heart. Here, we mention as an example noradrenaline which can act in an autocrine and para-
crine fashion: there is evidence for the presence, synthesis (and degradation), and intracellu-
lar action of noradrenaline in heart muscle cells on β- [28] and α-adrenoceptors (most of the 
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latter being detected intracellularly in the nuclear membrane, for overview [29]). We speculate 
that the 5-HT-receptors (which are phylogenetically assumed to be much older than adre-
noceptors) might also be detectable intracellularly in cardiomyocytes when more sensitive 
techniques will become available (Figure 1). It is notoriously difficult to detect endogenous 
G-protein-coupled receptors with specific, highly sensitive antibodies. Progress in this regard 
would be highly desired. Interestingly, 5-HT can exert intracellular effects via oxidation of 
5-HT in mitochondria (e.g. in mouse heart) and formation of free radicals. In that way, 5-HT 
Figure 1. Hypothetical fates of 5-HT in the mammalian heart. Ca2+ enters the mammalian heart cell via the L-type Ca2+ 
channel (LTCC). This process can be enhanced by 5-HT via a cascade starting with the 5-HT
4
 receptor (inhibitable by 
GR113808) occupation of which by 5-HT elevates activity of adenylyl cyclase (AC) in the sarcolemma via stimulatory 
G-proteins (Gs), elevates subsequent production of cAMP, and thereby activates cAMP-dependent protein kinase 
(PKA). PKA increases cardiac force generation and relaxation by increasing the phosphorylation state (P) of LTCC, 
phospholamban (PLB), and other regulatory proteins. Trigger Ca2+ initiates release of Ca2+ from the sarcoplasmic 
reticulum via ryanodine receptors (RYR) into the cytosol. There, Ca2+ activates myofilaments and this activation leads 
to increased inotropy. In diastole, Ca2+ is taken up into the sarcoplasmic reticulum via a sarcoplasmic reticulum Ca2+ 
ATPase (SERCA), the activity of which is enhanced due to an increased phosphorylation state of PLB. We tentatively 
propose that 5-HT is stored in cardiomyocytes in a hypothetical locus from which it can be released by compound 
48/80 and extruded from the cardiomyocytes, possibly via OCT2 and/or OCT3 and/or PMAT (inhibitable by cortisone, 
decynium 22). From the outside of the cardiomyocytes, 5-HT might be pumped back into the cardiomyocyte via SERT 
(inhibitable by fluoxetine). 5-HT might be formed in cardiomyocytes from tryptophan (Trp) via the enzyme tryptophan 
hydroxylase to generate 5-hydroxytryptophan (5-HTP) and thereafter decarboxylated by AADC (inhibitable by 
NSD1015) to 5-HT that is degraded via MAO-A (inhibitable by tranylcypromine) and its metabolites are substrates 
for aldehyde dehydrogenases (ALD; disulfiram-sensitive) or xanthine oxidases (XO; allopurinol-sensitive). In addition, 
one can speculate that 5-HT can pass through the outer nuclear membrane via OCT and then activate the inner nuclear 
membrane located 5-HT
4
 receptor which activates than AC via Gs leading to phosphorylation of substrates in the 
nucleus and to altered gene transcription.
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can also act receptor independently, at least in high concentrations to lead to apoptosis and 
necrosis, at least in the mouse heart [17, 30].
Furthermore, 5-HT can form covalent links to intracellular proteins and thence altering their 
functional role: transglutaminases can initiate covalent binding of 5-HT to fibrinogen, to small 
G-proteins, and to several other proteins present in platelets (review: [31]).
On the surface of platelets, a 5-HT2A-receptor is known to be expressed. Its activation will activate thrombosis. 5-HT is thought to enter platelets via serotonin transporter (SERT) (for 
review, see Refs. [32, 33]). Within the platelet, 5-HT is either degraded via oxidation or trans-
ported via Vesicular monoamine transporter (VMAT) into vesicles in platelets which will store 
(VMAT1 and VMAT2 are also present in other non-neuronal cells, saliva cells [34], and renal 
tubular cells [35]; it is worthwhile to try to detect VMAT in cardiomyocytes, which has appar-
ently not yet been reported) 5-HT and protect 5-HT from degradation. Upon an appropriate 
stimulus, 5-HT containing vesicles can reach the outer membrane of the platelets, fuse, and 
release 5-HT out of the platelets into the plasma. It has been shown that high blood platelet 
levels of 5-HT can serotonylate the protein rab4, which then inhibits the shift of SERT from 
the sublemmal space into the plasmalemma and hence quantitatively reduces its own uptake 
via SERT into platelets (which has been suggested to be of pathological relevance). There, 
5-HT can act via the above-mentioned receptors in an autocrine or paracrine way [31, 36, 37]. 
Moreover, it stands to reason that 5-HT produced within cardiomyocytes might also exit the car-
diomyocyte wherein it was formed (speculatively using uptake 1 or 2 and/or SERT, see below) to 
act in an autocrine or paracrine fashion at least under pathophysiological conditions.
5-HT can be compartmentalized in relevant cells: in peritoneal mast cells from rats, 5-HT was 
not only present in storage vesicles but also in the nucleus [38]. It is possible that mast cells 
produce relevant amounts of 5-HT because they contain their own TPH1 [19]. Compound 
48/80 can release 5-HT from mast cells and PCPA (an inhibitor of TPH activity) can reduce 
the levels of 5-HT in the cytosol of mast cells but not the nucleus of mast cells [38]. Likewise, 
clorgyline (a MAO-A inhibitor) and fluoxetine (a SERT-inhibitor) could decrease the cytosolic 
but surprisingly also the nuclear amounts of 5-HT in mast cells [38]. These data argue for the 
existence of functionally distinct subcellular pools of 5-HT. Similar studies in cardiomyocytes 
are apparently lacking and are keenly awaited.
5-HT is not only produced in the mammalian body but also in the plant kingdom and is found 
in foodstuff such as nuts, bananas, oranges, coffee, and peaches [39]. This might be an addi-
tional source of 5-HT reaching the heart. Finally, there are data that in the lumen of the gut, 
bacteria form 5-HT, which may be absorbed and may also reach the heart [40]. Uptake via the 
intestine could be achieved by SERT which present and active in epithelial cell of the gut (in 
crypts of intestine, rat [41]).
4. Enzymes for synthesis of 5-HT in the heart
The isoform TPH1 is mainly expressed in the gut (but also in the pineal gland [21]), whereas 
TPH2 is mainly found in the CNS (but also in enteric nerve cells [21, 36]). Knockout of TPH1 
reduced cardiac (adult mouse) 5-HT levels to about 10% of wild-type levels, indicating a relevant 
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production of 5-HT in the heart [21]. Some TPH1-knockout mice exhibited signs of left ventricu-
lar systolic failure without histologically detectable fibrosis [21] suggesting beneficial effects of 
the presence of 5-HT for cardiac function. In RNA from HL-1 cells and neonatal rat heart cells 
in Northern blots, TPH1 was detectable and TPH2 was missing [22] (similarly in adult hamster 
heart [42]). In RNA prepared from whole adult mouse hearts, TPH1 but not TPH2 was detected 
by PCR [43, 44]. Western blotting revealed low levels of TPH1 in mouse and rat adult heart 
homogenates. Fittingly, with the same antibody under similar conditions, no signal for TPH1 
was noted in TPH1-knockout mouse hearts [44]. However, the localization of TPH is uncertain: 
in rat hearts in immunohistology, TPH1 was located only in cardiac mast cells, but in mouse 
heart no signal was noted in cardiac mast cells [44]. This might be explained by the antibody 
used, as others detected in immunohistology TPH in mouse cardiomyocytes as well as human 
atrial cardiomyocytes [45]. Amino acid decarboxylase (AADC, which is identical to dopamine 
decarboxylase [46]) on mRNA level was detected in heart (by PCR in neonatal rat cardiomyo-
cytes but not in non-cardiomyocytes from neonatal rat hearts [22]). Subsequently, the activity of 
AADC will result in the generation of 5-HT. In apparent contrast to neonatal cardiomyocytes, 
AADC was detected via Western blotting in endothelial cells but not in cardiomyocytes of adult 
rat hearts and adult mouse hearts [44]. Whether this is due to age differences or lack of translation 
of RNA or too low protein levels of AADC or the features of the antibody used is still an open 
question. Others, however, noted in immunohistology the presence of AADC also in cardiomyo-
cytes using slices from adult mouse heart and human right atrium [45]. Moreover, addition of 
5-hydroxytryptophan (5-HTP, the direct precursor of 5-HT) enhanced 5-HT levels in these iso-
lated cardiac mouse myocytes [23]. Interestingly, 5-HTP can exert functional effects in the heart. 
More specifically, in electrically driven left atrial preparations of transgenic mice (which overex-
press the human 5-HT
4
-receptor in the heart, see below), 5-HTP exerted time- and concentration-
dependent positive inotropic effects (PIE) or increased the beating rate [positive chronotropic 
effect (PCE)] of right atrial preparations [45, 47]. Injection of 5-HTP into intact mice led to an 
increase of 5-HTP but allows of 5-HT in the cardiac tissue of mice [44]. Injection of benzerazide 
in intact mice, in contrast, reduced the cardiac levels of 5-HT [44]. Likewise, 5-HTP exerted a PIE 
in atrium from 5-HT
4
 overexpressing mice or human right atrial preparations [47] (Figure 2). 
These contractile effects were blocked by NSD-1015 (Figure 2), suggesting they result from the 
enzymatic formation of 5-HT in these mouse or more importantly human cardiac preparations. 
Similarly, injection of 5-HPT in living whole mice (and in isolated buffer perfused hearts) led to a 
measurable increase in the cardiac content of 5-HT [44], and the effect was blocked by injection of 
benzerazide (an AADC inhibitor, used in treatment of Parkinson’s disease). The authors posited 
that 5-HTP derived from platelets led to 5-HT synthesis in the heart [44]. In earlier work in the 
kidney, infusion of 5-HTP led to vasoconstriction which was reversed (or block by pretreatment) 
with carbidopa (a dopa decarboxylase inhibitor [48]). Infusion of 5-HTP led to increased levels of 
5-HT in the renal venous effluent and in urine and these elevations of 5-HT returned to baseline 
values if carbidopa was additionally applied. These data are consistent with renal formation of 
5-HT from 5-HTP via dopa decarboxylase activity [48].
A drawback of these pharmacological experiments is always that their interpretation is highly 
dependent upon the specificity of the inhibitory drugs used. It would be useful to refute or 
confirm these pharmacological experiments by studying cardiomyocytes from mice with 
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cardiac-specific knockout of TPH1 and/or aromatic L-amino acid decarboxylase (AADC). 
Data for the local generation of 5-HT in peripheral arterial tissue (rat aorta, isolated human 
arterial coronary smooth muscle cells) are available and argue for local production and 
release independently of plasma or platelet levels of 5-HT [49, 50]. When one studied cardiac 
Figure 2. Typical original recording of isolated electrically stimulated trabeculae from a human atrium. The ordinate 
indicates force of contraction in milli Newton (mN), and the abscissae indicate time in minutes exemplified by scale bars. 
Of note, 5-hydroxytryptophan increases force of contraction (lane 1) and this effect was gone in the presence of NSD 
1015, suggesting that 5-HT formation is necessary. NSD always exerted a small contractile effect of unknown origin. 
Isoproterenol, an unselective β-adrenoceptor agonist, was used as positive control.
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tissue in adult human autopsies, in 72 or 80% of neurons within cardiac ganglia, tryptophan 
hydroxylase or dopa-decarboxylase immune reactivity was found, respectively, using com-
mercial antibodies [51]. These levels were reduced in the presence of p-chlorophenylalanine 
(PCPA, an irreversible inhibitor of tryptophan hydroxylase activity) or 3-hydroxy-benzyl-
hydrazine (NSD-1015), an inhibitor of aromatic L-amino acid decarboxylase (AADC [23]). 
Moreover, addition of 5-hydroxytryptophan (the direct precursor of 5-HT) enhanced 5-HT 
level in these isolated adult cardiac mouse myocytes [23].
5. Enzymes for degradation of 5-HT in the heart
As mentioned above in non-cardiac tissues, 5-HT is probably degraded by MAO-A. The same 
probably holds true for adult cardiac myocytes: levels of 5-HT were greatly elevated in the 
presence of tranylcypromine (clinically used as an antidepressant, inhibiting both MAO-A 
and MAO-B [23]) or in the presence of clorgylin (a MAO-A inhibitor [23]) but not by deprenyl 
(clinically used to treat Parkinson’s disease, because it inhibits MAO-B [23]). MAO is especially 
active in gut, liver, and serotoninergic nerve cells. However, species differences exist. MAO-B 
is much less active in rat heart than MAO-A, and in human heart MAO-A and MAO-B are 
equally active [52]. The total activity of MAO is 100 times higher in the rat than in the wild-
type mouse heart [53]. Likewise, MAO-B is mainly active in mouse heart, compared to MAO-A 
[54]. Hence, knockout of MAO-A in mice is probably not all that physiologically relevant for 
the human situation. At least in rat using ligand-binding experiments, even the regional car-
diac distribution of MAO was found to be regionally different: there is a fivefold difference in 
MAO-A levels in parts of the ventricle of rat hearts [55]. The study of 5-HT levels in human 
cardiac tissue (preferably in cardiomyocytes, which is technically not highly reproducible, or 
stem cells, which have their own pitfalls) in the absence or presence of selective MAO inhibi-
tors or genetic reduction of MAO levels in human cardiomyocytes are awaited with eagerness. 
Moreover, 5-HT can also be metabolized by the acrylalkylamine-N-acetyltransferase (present 
in the heart [56]). 5-HT can be degraded by MAO-A or MAO-B to 5-hydroxy-indole-acetal-
dehyde and by action of unspecific dehydrogenases and/or alcohol dehydrogenase 2 finally 
to 5-hydroxy-indole-acetic acid which leaves the body via the kidneys, and its concentration 
has been used in patients to monitor the presence of 5-HT-producing carcinoid tumors [26, 
57]. Based on knockout experiments, 5-HT in the mouse is mainly degraded by MAO-A not 
MAO-B [58]. Inhibition of the activity of MAO by tranylcypromine potentiated the PIE of 5-HT 
in atrial preparations of 5-HT
4
-receptor overexpressing mice [24]. 5-HT can also be metabo-
lized by an indoleamine 2,3-dioxygenase (the rate limiting step in this pathway, with immu-
nohistology detected in cardiomyocytes and active in mouse heart [59]) to kynurenine (present 
in mouse heart [60]). Indoleamine 2,3-dioxygenase (IDO) can be induced in infectious diseases 
like cardiac viral myocarditis [59]. Studying knockout mice for this enzyme supported an 
important role of IDO in acute viral myocarditis [59]. Furthermore, 5-HT can be metabolized 
even into melatonin (recent publication on levels of melatonin in rat heart: [61]) by hydroxy-
indole O-methyltransferase (enzyme present and active in mammalian heart: [56]) in the heart 
and this melatonin may play a role in protection against cardiac ischemia [62].
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6. Uptake 1 of 5-HT in the heart
Classically, re-uptake of 5-HT (but also of neurotransmitters like histamine, noradrenaline, 
or dopamine) into nerve cells has been called uptake 1 and is assumed to be mediated for 
5-HT by SERT (and by dopamine transporter (DAT) for dopamine, as well as by noradren-
aline transporter (NAT = NET) for noradrenaline, however, their specificity of transport 
shows some overlap, which may explain compensations in knockout mouse models [63]). 
SERT is blocked by some antidepressant drugs like fluoxetine. Likewise, genetic deletion 
of SERT (total knockout) led to a decrease of 5-HT levels from 29 to 0.4 μM in whole blood, 
probably as a result of lack of reuptake via SERT into platelets, clearly indicating that SERT 
is not only active in the central nervous system but also in the periphery. Uptake 1 is energy 
dependent because it acts against a neurotransmitter gradient. Uptake 1 can also be blocked 
by cocaine (which is, however, unspecific because it blocks at least also NAT and DAT). 
Interestingly, the EC50 of 5-HT in the presence of cocaine for the PIE is much smaller in human isolated atrial preparations (39 nM) than in the absence of cocaine (230 nM: [64]): 
this could mean that cocaine inhibits the uptake 1 into nerve cells or that it inhibits reuptake 
of 5-HT into cardiomyocytes by inhibiting SERT in cardiomyocytes. At low concentrations 
of 5-HT (50 nM), about 70% of 5-HT is taken up via uptake 1 (the remainder via uptake 2 
see below). SERT has been found in the lung (endothelial cells and smooth muscle cells: 
[65]; rat aorta: [49]) on cardiac valves (rat: [66], dog: [67], human valvular tissue: [43]), con-
duction system of the mouse, mouse cardiomyocytes, and mouse cardiac endothelial cells 
[68–70]. At least in fetal cardiomyocytes, SERT was seen in immunohistology [71]. Some 
detected SERT in the endocardium and endothelium of coronary arterial cells and capillar-
ies, while they failed to detect SERT in cardiomyocytes from adult mice [43]. Others using 
different experimental conditions detected SERT in cardiomyocytes from adult mouse 
heart and human right atrium [45]. Functional evidence for the activity and therefore pres-
ence of SERT are also available: 5-HT, applied in cell culture of adult rat ventricular myo-
cytes induced cellular hypertrophy and this hypertrophy was attenuated by imipramine 
[72, 73]. This is functional proof that cardiomyocytes can take up 5-HT and might argue 
for an involvement of SERT in this process. Knockout of SERT in mice was accompanied 
in whole blood by an about 10-fold reduction of 5-HT levels [43]. Interestingly, adult mice 
with global knockout of SERT showed left ventricular dilatation and systolic heart failure 
(decreased fractional shortening in echocardiography) which was accompanied and possi-
bly caused, in part, by cardiac ventricular interstitial fibrosis as well as cardiac valve fibrosis 
effects present also on 5-HT1B-receptor knockout mice and hence not 5-HT1B-receptor medi-
ated [43]. SERT is reversible in its transporter function: during ischemia, in the presence of 
tyramine of amphetamines, intracellular 5-HT can leave mouse cardiomyocytes [68]. The 
functional role of SERT in the heart is evident from the observation that fluoxetine can 
shift the concentration response curve for the positive inotropic effect of 5-HT to lower 
concentrations of 5-HT in the left atrium of mice overexpressing the 5-HT
4
-receptor [24]. A 
prominent pathway is initiated by the enzyme indoleamine-2,3-dioxygenase (IDO, which 
opens and destroys the indole ring system of tryptophan), which feeds into the so-called 
kynurenine pathway (review: [19]).
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7. Uptake 2 of 5-HT in the heart
Uptake of neurotransmitters (like 5-HT) into non-neuronal cells (such as smooth muscle 
cells, fibroblasts, endothelial cells, or cardiomyocytes—have been called “uptake 2”) and is 
assumed to be mediated by proteins such as OCT1, OCT2, OCT3, and PMAT. Uptake 2 is not 
energy dependent because it follows a neurotransmitter gradient. Another difference between 
uptake 1 and 2 relies on the fact that uptake 2 is much less specific for 5-HT than uptake 
1. Usually, proteins that comprise uptake 2 will also transport other neurotransmitters like 
dopamine and noradrenaline [63]. Uptake 2 is usually inhibited by cortisone (but also by 
synthetic dexamethasone, by aldosterone, and by budesonide) via unknown mechanisms and 
divergent specificity for OCT1-3 and PMAT [63, 74]) and more specifically by decynium 22 
[57, 63]. At higher concentrations of 5-HT (10 μM), it is mainly transported via uptake 2 (in 
synaptosomes, regarding decynium 22 as uptake 2-specific [57]). In the CNS, proteins respon-
sible for uptake 2 have been detected not only in nerve cells but also in non-nerve cells (glial 
cells [63]). Uptake 2 is functionally relevant in the heart because decynium 22 affects the con-
centration response curve of 5-HT on force of contraction in isolated atrium of 5-HT
4
-receptor 
overexpressing mice [24]. OCT2, OCT3, and PMAT have been detected by immunohistology 
in mouse or human cardiomyocytes [45] and by immunofluorescence (OCT1, OCT3) in the 
human heart [75].
8. Inotropic effects of 5-HT in the heart, species differences
A positive inotropic effect (PIE) of 5-HT was described in the heart of many mammalian spe-
cies. More specifically, a PIE was described in cardiac preparations from cats, guinea pigs, 
dogs, pigs, and rats [76–80]. The PIE in cats is indirectly mediated via release of endogenous 
noradrenaline [81]. The PIE in the same species can be region dependent: for instance, in 
rats, a PIE in left atrium but not in papillary muscle was reported [82]. Similarly, in human 
atrial but not ventricular preparations, 5-HT exerted a PIE [83, 84]. Later, it was noted that in 
ventricular preparations from patient in end-stage heart failure a noteworthy effect of 5-HT 
was detectable and this effect was more pronounced in the presence of the phosphodies-
terase inhibitor 3-isobutyl-1methylxanthine (IBMX) [85]. Interestingly, similar findings were 
reported in pigs: only in the presence of IBMX in ventricular preparations of pigs, a PIE to 
5-HT could be noticed [86] suggesting that the low number of 5-HT
4
-receptors was unable to 
raise cyclic-3’,5’-adenosine monophosphate (cAMP) levels to inotropically relevant levels in 
the presence of substantial endogenous unopposed phosphodiesterase activity in ventricular 
preparations of humans and pigs. In isolated paced left atrial preparations of wild-type mice, 
no PIE in the absence [87] or presence (Käufler, Gergs, Neumann, unpublished observations, 
2017) of 100 μM IBMX to 5-HT (1 nM–1 μM) was, however, observed, underscoring species 
differences. The EC50 value for the PIE of 5-HT in isolated preparations from human right atrium was between 309 and 230 nM [80]. In mouse adult cardiomyocytes, the 5-HT level was 
estimated to amount to 2.9 pmol/mg protein [23]. Concentrations of 5-HT in isolated sam-
ples from human hearts (freshly frozen, after autopsy, from the right atrium, from papillary 
muscles) were reported from 0.08 to 0.4 μg/g [15], recalculated as about 0.45 to 2.3 μM. Such 
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differences might be due to contamination with platelets (for very high values) or postmortal 
degradation (for low levels). Assuming a homogenous distribution of 5-HT in isolated mouse 
adult cardiomyocytes, intracellular concentrations of 200 nM for 5-HT have been calculated 
[23]. These concentrations are well in the range of EC50 values for the 5-HT-receptors like those responsible for inotropy in some mammalian species including humans [20, 88]. At high 
concentrations of 5-HT for prolonged times in the organ bath, a second negative inotropic 
effect of 5-HT was noted, which was alternatively explained as desensitization by activation 
of phosphodiesterases [89]. Homologous desensitization in the isolated atrium (also in left 
ventricle of the living animal) can be clearly shown for the PIE effect of 5-HT in 5-HT
4
-receptor 
overexpressing mice [90, 91] like in isolated human cardiac preparations (review: [92]).
9. Chronotropic and proarrhythmic effects of 5-HT in the heart
Positive chronotropic effects of 5-HT were noted in isolated atrial preparations of rats [93], 
cats [94], pigs [95] as well as guinea pigs [96] and awake humans [14]. Even bradycardia can 
be elicited by 5-HT via the von Bezold-Jarisch reflex [97]. In whole pigs and isolated pig car-
diac preparations, 5-HT increased the heart rate via 5-HT
4
-receptors [86, 92, 98]. It is assumed 
that the effect is brought about by 5-HT
4
-receptors initiating a cascade via Gs, AC, cAMP and 
then activating hyperpolarization-activated, cyclic nucleotide-gated cation  channels (HCN) 
in the sinus node [86]. 5-HT increased the HCN-coded current called I
f
 in isolated human 
atrial cardiomyocytes and was mediated by 5-HT
4
-receptors (using specific receptor antago-
nists [99–101]). In one of the first studies on humans, 5-HT induced cardiac arrhythmias in 
vivo (tachycardia and P wave inversions in two patients: [14]). Interestingly, 5-HT induced 
arrhythmias even in isolated electrically driven human atrial cardiomyocytes, proving that 
arrhythmia does not need indirect pathways but is sufficiently explained by direct activation 
of receptors (5-HT
4
-receptors) [102]. Interestingly, the incidence of arrhythmias was enhanced 
in isolated atria from humans treated prior to surgery with β-adrenoceptor blockers [102, 
103]. The arrhythmias could be explained on a single cell basis via late afterdepolarizations 
[104, 105]. In addition, arrhythmogenesis due to 5-HT might also involve stimulation L-type 
Ca2+-channels and potassium channels [86, 106]. 5-HT may also be relevant to sustain an 
existing arrhythmia: during pre-existing atrial fibrillation, more 5-HT will be released from 
thrombocytes [107]. This can increase local concentrations of 5-HT, which can act on 5-HT
4
-
receptors to sustain fibrillation (for further hypothetical mechanisms: [92]). Mechanistically 
interesting is the observation that in some children autoantibodies against 5-HT
4
-receptors 
exist which have been suggested to lead to AV blocks in neonates [108]. In 5-HT
4
-receptor 
overexpressing mice, arrhythmias under basal conditions or after 5-HT stimulation have been 
observed [23, 87, 109]. The 5-HT
3
-receptor might be antiarrhythmic: general deletion of the 
5-HT
3
-receptor in mice led to spontaneous ventricular tachycardia and increased sudden 
death in pregnant mice. It was speculated that 5-HT
3
-receptor blockers should therefore be 
avoided in pregnant women [110]. Consistent with this, ondansetron, a blocker of 5-HT
3
-
receptors, has been reported to elicit arrhythmias in patients [111]. In addition, prolongation 
of P-waves and highly elevated T-waves (interpreted as a sign of repolarization abnormali-
ties) were described in mice with knockout of 5-HT2B-receptors [112].
Production and Function of Serotonin in Cardiac Cells
http://dx.doi.org/10.5772/intechopen.69111
281
10. Effects of 5-HT on cardiac vasculature, species differences
5-HT can induce vasoconstriction also in coronary arteries [20]. During reperfusion of coro-
nary arteries, 5-HT can have detrimental effects like apoptosis and necrosis [72]. In man, a 
more subtle picture emerges: without endothelium or in defective endothelium (arterioscle-
rosis, coronaries injected in vivo with 5-HT in patients having received transplanted hearts), 
5-HT induces vasoconstriction, but in the presence of functional endothelium, 5-HT induces 
vasodilation in human coronary arterial strips [113–115]. Others noted in human coronary 
vessel strips with intact endothelium (obtained from transplanted hearts) a 5-HT-mediated 
vasoconstriction that was in part ketanserin-sensitive [116]. In isolated strips from human pul-
monary veins or arteries, 5-HT led to vasoconstriction (regardless of the presence or absence 
of endothelium) and was interpreted to be mediated by 5-HT
2
- and 5-HT1-receptors while ligand-binding studies presented evidence for the expression of 5-HT
4
-, 5-HT2A-, and 5-HT1D-receptors in these tissues [117]. In summary, vasoconstriction can be mediated by 5-HT2A- and 
5-HT1D-like receptors and the latter are more relevant for vasoconstriction [114, 118].
11. Use of genetically modified mice to study functional effects of 5-HT  
in the heart
Gain of function animal models like mice that overexpress in a cardiac specific way 5-HT
4
-
receptors [87], MAO-A [119], 5-HT2B-receptors [120] or SERT [121] have been described and used to better understand the role(s) of 5-HT in the mammalian heart. However, animal 
models with loss of function are much more abundant (Table 1). The cardiac phenotypes of 
mice overexpressing SERT or 5-HT
4
-receptors (in the heart) have been discussed in this text. 
5-HT2B-receptor overexpressing mice, however, had no defect in systolic function (unaltered ejection fraction). Interestingly, their heart weight to body weight ratio was increased (cardiac 
hypertrophy). This was explained by an increase in the number and size of cardiomyocytes. 
Further changes were an increase in the number and activity of mitochondria in hearts from 
transgenic mice but no cardiac fibrosis was noted. It is possible that the hypertrophy is due 
to constitutive activation of the PLC pathway by the overexpressed 5-HT2B-receptor [120]. Interestingly, in 5-HT2B-receptor knockout mice (made by the same group), a dilated cardio-myopathy (with decreased systolic function, small sized cardiomyocytes) was noted [112] 
(Table 1). Surprisingly, the knockout of the 5-HT2B-receptor exhibited gender-specific differ-ences in the phenotype. For instance, ECG alterations (prolongation of P-wave) were more 
pronounced in female than male 5-HT2B knockout mice [112].
To the best of our knowledge, mice with cardiac-specific knockout of the genes listed in 
Table 1 have not been described in the literature and might be meaningful new study sys-
tems. In addition to the mouse models listed in Table 1, there is also a SERT knockout rat in 
the literature [147]. This rat model should be useful in some regards, because historically most 
work on hypertension was done in rats. In this context, mice with cardiac-specific overexpres-
sion of 5-HT2B-receptors could be generated by mating 5-HT2B knockout mice and 5-HT2B-receptor overexpressing mice, an interesting line of research for other 5-HT-receptors [148].
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12. 5-HT-receptors present in the heart: cell and species differences
The current thinking is that 5-HT can act via membrane bound receptors called 5-HT1-7 ([20, 149], review: [150]). The 5-HT
3
-receptor is a ligand-gated ion channel, whereas all other 


















5-HTT (SERT) Serotonin-transporter [133–135]
TPH1 Serotonin synthesis [21, 37]
Dopa-decarboxylase Serotonin synthesis [136]
MAO-A Serotonin degradation [137]
MAO-B Serotonin degradation [138]
VMAT1 Serotonin uptake [139]
VMAT2 Serotonin uptake [140]
PMAT Serotonin uptake [141]
OCT1 Serotonin uptake [142]
OCT2 Serotonin uptake [143]
OCT3 Serotonin uptake [144]
IDO Serotonin degradation [59]
Alcohol dehydrogenase Serotonin degradation [145]
Xanthine oxidase Serotonin degradation [146]
Table 1. Constitutive knockouts of genes relevant for serotonin handling.
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subsequently diacylglycerol can activate PKC. Moreover, 5-HT2A- and 5-HT2C-receptors can also activate phospholipase A
2
. In the whole mouse heart, the following receptors have been 
described on mRNA level: 5-HT1A-, 5-HT1B-, 5-HT1D-, 5-HT2A-, 5-HT2B-, 5-HT2C-, 5-HT3-, and 
5-HT
4
-receptors [43]. Surprisingly, others failed to detect the 5-HT
4
-receptor in mouse heart 
and only reported on 5-HT2A- and 5-HT2B-receptors [151]. Others failed to detect 5-HT2C-receptors in neonatal rat cardiomyocytes, which offers the possibility that the cardiac expres-
sion of 5-HT-receptors might be developmentally regulated or likewise be species dependent 
or in different cell types of the heart [22]. Apparently, the 5-HT6-receptor was not found by PCR in adult mouse whole hearts [43]. Four isoforms of mouse 5-HT
4
-receptors exist (on RNA 




-receptors are also present in 
human atrium [153, 154] and to a lesser extent in human cardiac ventricle [85, 155]. As men-
tioned before, 5-HT2A-receptors mediate the effects of 5-HT in thrombocytes [156]. The PIE of 5-HT in rat atrium is probably mediated by 5-HT2A-receptors [82]. 5-HT2A- and 5-HT4-receptors are, however, present on RNA in rats [82], but the 5-HT
4
-receptors in rat hearts only become 
functional (mediating a PIE) in stress (myocardial infarction: overview in [157]). The 5-HT
2
-
receptors can activate phospholipase C and can elevate IP3 levels in the rat heart [82]. 5-HT2A-receptors are found in human arterial smooth muscle cells and can lead to vasoconstriction 
[158, 159]. Initially, 5-HT
3
-receptors seemed only to be present in nerve cells in the heart and 
might mediate the “von Bezold-Jarisch” reflex [97]. The 5-HT
3
-receptors seem to be found in 
epicardial afferent sensory nerve ending of the vagus [160]. More recently, however, using a 
new knockout mouse, 5-HT
3
-receptors were found at least in the ventricle of wild-type mice 
[110]. The 5-HT
4
-receptor (but not, for instance, a 5-HT
2
-receptor) mediates the PIE and PCE 
in the human heart [64, 92]. The study of the 5-HT
4
-receptor structure is complicated because 
many splice variants are known which might have different physiological and/or pathophysi-
ological roles [157]. No convincing antibodies to 5-HT
4
-receptors let alone for splice variants 
have been published in the literature (and our own unpublished observations). Hence, protein 
levels of these receptors are difficult to assess. At least, some radioactive ligand-binding stud-
ies shed some light on the protein expression levels in the heart and found measurable but 
very low densities of 5-HT
4
-receptors in the heart [161]. Really specific antibodies for 5-HT
4
-
receptors with high affinity are highly desirable. 5-HT1-receptors are present in endothelial cells and smooth muscle cells in human coronary arteries and mediate vasoconstrictory effects 
of 5-HT [158] and can inhibit AC activity [162]. PIE of 5-HT in human atrium and ventricle 
are 5-HT
4
-receptor mediated (trabeculae: [64]). 5-HT2B-receptors are present in cardiac valves. Their simulation by 5-HT, fenfluramine (indirectly by inhibiting SERT or by releasing 5-HT 
from platelets), ergotamine derivatives, methysergide, and recreational drugs (“ecstacy”) can 
lead to deadly valve ruptures [163–165]. Typically, these drugs are present in all parts of the 
blood circulation; hence, the valve dysfunction can take place in the right as well as in the 
left heart. An excellent review on 5-HT-receptors in the vascular system especially the heart 
of humans is to be found in the literature and will be helpful for in depth information [157].
13. Signal transduction mechanisms of 5-HT-receptors in the heart
Moreover, 5-HT in isolated atrial preparations from human hearts increased cAMP con-
tent, PKA activity [64, 80], and the phosphorylation state of phospholamban (PLB) and the 
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inhibitory subunit of troponin (TNI, [88]), and these effects were blocked by 5-HT
4
-receptor 
antagonists [88]. Hence, these effects were probably 5-HT
4
-receptor mediated [88]. In elec-
trophysiological experiments, 5-HT elevated the L-type Ca2+-current in human atrium [83, 
166, 167] but not human ventricle [83, 168]. Mechanistically important, 5-HT increased the 
contractility in isolated atrial paced human cardiomyocytes [103]. Stimulation of 5-HT2A-receptors led to increases of IP3 content [82]. Similarly, in transgenic mice that overexpress 
5-HT
4
-receptors in the mouse heart, 5-HT led to PIE and PCE in intact mice (using echo-
cardiography), in isolated perfused hearts, in isolated left atria (electrically driven), or iso-
lated spontaneously beating right atria. These effects were accompanied by cAMP increases, 
increased phosphorylation state of PLB (on amino acid serine 16 and threonine 17), increase 
in current through L-type Ca2+-channels, and increase in the free Ca2+ content in the cytosol 
in mice ventricular preparations or whole hearts [87]. In addition, increased phosphorylation 
of PLB was also noted in atrial preparations from 5-HT
4
-receptor overexpressing mice [169]. 
In these mice, the in vivo activity of agonists could be studied on contractility [90]. Here, 
one can recapitulate findings in cloned receptors, for instance, cisapride was less potent and 
effective to increase force of contraction than 5-HT. Moreover, cisapride induced concentra-
tion-dependent tachycardia (and arrhythmias) in spontaneously beating isolated right atrial 
preparations of 5-HT
4
-receptor overexpressing mice [170], similar to tachycardias described 
in some patients treated with cisapride [171]. However, prucalopride was less potent but 
equieffective compared to 5-HT [109, 170, 172]. In addition, 5-HT is able to desensitize the 
5-HT
4
-receptor not only in 5-HT
4
-receptor overexpressing mice in the atrium [90] but also in 
the ventricle [172, 173]. LSD and ergotamine in vitro displayed biased signaling for β-arrestin 
at 5-HT2B- and 5-HT1B-receptors [174].
14. Altered expression or function of cardiac 5-HT or its receptors under 
pathophysiological conditions
14.1. Carcinoid syndrome
In the carcinoid syndrome (typically due to tumors arising from enterochromaffin cells of 
the gut that in 10% of cases produce high levels of 5-HT: cf. [23] for a clinical example, large 
patient series: [26]), high circulating levels of 5-HT, which can stimulate 5-HT-receptors, and 
lesions of the right cardiac valves have been reported. Normally, the pulmonary circulation is 
assumed to remove free circulating 5-HT from the plasma and very little 5-HT in the plasma 
would reach the left ventricle (discussed in Ref. [43]). However, when a carcinoid tumor is 
located to the lung or an open foramen ovale is present or exceedingly high plasma 5-HT 
levels occur from a carcinoid in the gut or liver, which would spill over into the pulmonary 
veins, left cardiac lesions like valve failure have also been noted [43].
14.2. MAO-dependent oxidative stress
By altering cardiac levels of 5-HT, MAO might be of clinical relevance in patients. This can 
be tentatively concluded from the following animal studies. Cardiac-specific overexpression 
of MAO-A (in mice) led to decreased cardiac levels of 5-HT (and noradrenaline). This was 
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accompanied by increased levels of free radicals in the mouse heart, as well as oxidation of 
mitochondrial DNA, cardiac fibrosis, and ventricular heart failure [53]. Oppositely, a knock-
out of MAO-A in mice was functionally beneficial because it reduced left ventricular dilatation 
and left ventricular dysfunction after hypertension (via aortic banding). Accordingly, aortic 
banding (an experimental model to increase cardiac afterload) increased protein levels of 
MAO-A threefold [119]. High cardiac concentrations of 5-HT can lead to cardiac hypertrophy 
(and later on, possibly, to heart failure, see below) via receptor-independent mechanism(s) 
or 5-HT-receptor-dependent mechanisms. In more detail, high cardiac intracellular levels of 
5-HT are oxidized in mitochondria via MAO activity: this leads to the generation of deleteri-
ous free radicals [119]. In aging rat hearts, MAO-A activity was increased, which may exacer-
bate deleterious effects of cardiac 5-HT [119]. In rat cardiac myocytes, high intracellular levels 
of 5-HT led to enhanced MAO-dependent oxidative stress followed by release of cytochrome 
c from cardiac mitochondria, upregulation of proapoptotic BAX protein, downregulation of 
antiapoptotic Bcl2 protein, and thus to detrimental apoptosis [72].
14.3. Hypertension
In peripheral arterial hypertension, more 5-HT can be found in the plasma, and via covalent 
modification of the protein rab4, the function of SERT in platelets is reduced and thus a circu-
lus vitiosus might start [175]. Moreover, it has been suggested that 5-HT might act on small 
G-proteins (by inducing serotonylation of these proteins) in smooth muscle cells in pulmo-
nary arteries, rendering the arteries more susceptible to 5-HT-induced vasoconstriction and 
thus leading to sustained pulmonary hypertension and death [36]. Serotonylation of several 
proteins in rat aorta has likewise been reported [176]. Pulmonary hypertension might be caus-
ally related to 5-HT: plasma levels of 5-HT are twofold to threefold higher in patients suffering 
from this disease and augmented 5-HT plasma levels may lead to constriction of pulmonary 
arteries and thus to pulmonary hypertension in humans [177]. This is in line with animal 
experiments: in TPH1 knockout mice, hypoxia (placing the animals into chambers with low 
partial pressure of oxygen) was less prone to rise right ventricular pressure compared to WT 
animals [178]. In a rat model of pulmonary hypertension (induced by monocrotaline), block-
ing 5-HT2B-receptors was protective for right ventricular function [179].
14.4. Cardiac hypertrophy
Interestingly, a blocker of 5-HT2A-receptors attenuated cardiac hypertrophy after aortic band-ing in mice, suggesting a role of this receptor in cardiac hypertrophy, and in this context, 
hypertrophy (transiently) increased the expression of the 5-HT2A-receptors in mouse cardio-myocytes after aortic banding [180]. The classical isoproterenol-induced hypertrophy in a 
mouse model was reduced in mice treated with a 5-HT2B blocker or in 5-HT2B-receptor knock-out mice, probably by inhibiting peroxide generation in mitochondria [2, 181]. Interestingly, a 
isoproterenol-induced cardiac hypertrophy (a classical animal model of hypertrophy) seemed 
to require 5-HT2B-receptors on cardiac fibroblasts [148]. Fittingly, in patients with cardiac hypertrophy, the expression of 5-HT2B-receptors was elevated (radioligand binding [148]). 
5-HT2B-receptors were detected with immunohistology in human cardiomyocytes and human 
Serotonin - A Chemical Messenger Between All Types of Living Cells286
non-cardiomyocytes; however, it is an open question (and a mechanistically very important 
question) whether overexpression of these receptors in human heart failure occurs in cardio-
myocytes and/or in non-cardiomyocytes [148].
14.5. Heart failure
In heart failure, 5-HT might be altered: increases in plasma 5-HT levels in patients with 
decompensated systolic heart failure [182] or diastolic heart failure [183] have been described. 
These studies concluded that 5-HT elevation may be a compensatory mechanism, trying to 
increase cardiac output by increasing heart rate and cardiac force [182]. In atrial samples 
from heart failure patients, the PIE of 5-HT was reduced. Moreover, biochemical correlates of 
receptor coupling like the extent to which 5-HT could increase AC activity [184] or increase 
L-type Ca2+-currents, was attenuated in samples from heart failure patients [168]. Some of 
these effects were reversed after β-adrenergic blockade of patients prior to surgery [185]. In 
a rat model of heart failure (infarction), the mRNA of 5-HT
4
-receptors increased and a robust 
PIE of 5-HT (which was lacking in normal rats without heart failure) became apparent [186]. 
Moreover, there are data that in human heart failure a PIE of 5-HT and upregulation of 5-HT
4
-
receptors become measurable [85, 155]. Interestingly, the PIE of 5-HT increased with NYHA 
class but the PIE of β-adrenergic stimulation decreased with NYHA class [85]. In a pilot study 
with heart failure patients, the EF increased after being treated with a 5-HT
4
-receptor antago-
nist (piboserod [187]). This might mean that activation of 5-HT
4
-receptors is deleterious in 
human heart failure. In apparent contrast to this conclusion, in lipopolysaccharide (LPS)-
induced sepsis (another accepted model of heart failure), overexpression of 5-HT
4
-receptors 
seemed to protect the heart by interference with the toll-like receptor 4 pathway [188].
14.6. Atrial fibrillation
In patients with chronic (more than 1 month persistent) atrial fibrillation, the expression 
of 5-HT
4
-receptor mRNA levels was found to be decreased by about 36% (irrespective of 
β-adrenoceptor treatment) in comparison to controls in sinus rhythm and this change in 
receptors level was suggested to be a protective mechanism [189]. Others found the expres-
sion of 5-HT
4b
-receptors to be downregulated (mRNA) in acute atrial fibrillation but upregu-
lated with atrial fibrillation lasting more than 1 year [190]. Protein data for 5-HT
4
-receptors in 
atrial fibrillation would clearly be desirable to resolve these somewhat contradictory findings. 
In aging, the uptake of 5-HT in platelets is augmented, concentrations of 5-HT in platelets are 
therefore higher, and thence 5-HT is more prone to induce aggregation of platelets and thus 
thrombosis (e.g. [191]).
14.7. Aging
At least in pigs, the PIE of 5-HT in atrium and ventricle in vitro is increased from neonates to 
adulthood [85, 86]. The opposite occurs in rats: fetal rat ventricles express highly the mRNA 
for 5-HT
4
-receptors and are accompanied by (and probably causes) a large PIE to 5-HT in neo-
natal cardiac preparation. In contrast, in adult rats, as mentioned before, 5-HT is devoid of a 
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PIE in the rat ventricle [82, 192]. In human atria, 5-HT stimulates AC less in aging, which was 
explained by increased levels of Gi proteins [193]. Hence, age-dependent changes in cardiac 
response to 5-HT are known, but much more refined data are clearly needed from further 
work.
So sum up these findings, it is possible that 5-HT causes or at least contributes to cardiac 
hypertrophy, arterial or pulmonary hypertension, heart failure, cardiac aging, and cardiac 
arrhythmias.
15. Possible cardiac side effects of serotoninergic drugs
Drugs elevating 5-HT: SERT inhibitors (specific serotonin reuptake inhibitors, SSRIs), they are 
suggested to increase 5-HT not only in brain synapses but also in cardiac tissue and there-
fore they might be implicated in arrhythmias (citalopram: [194]). Warning notices have been 
sent out for citalopram in this regard by regulatory authorities (FDA: 2012). A recent study 
noted enhanced risks of valve disease in patients who take SSRI [195], presumably because 
high plasma membrane concentrations of 5-HT activate 5-HT2B-receptors. 5-HTP has been suggested to be used as add on to SSRI in order to treat depression, because it is metabolized 
to 5-HT. 5-HTP is therefore predicted, indirectly, to lead to arrhythmias in patients.
5-HT1-receptors: Sumatriptan and congeners are well known to have the ability to contract coronary arteries and can lead to myocardial infarctions [196]. Buspirone is a drug acting 
among others on 5-HT1A-receptors and has been shown to lead to tachycardia.
5-HT
2
-receptors: Ergotamine and LSD (but also fenfluramine) stimulate 5-HT1B-receptors but also detrimental 5-HT2B-receptors (leading to valve fibrosis) [174]. In addition, an important metab-olite of fenfluramine called norfenfluramine could bind with high affinity to 5-HT2B-receptors and could stimulate in the receptor-transfected HEK cells the IP3 levels, presumably initiating 
fibroplasia in vivo in humans [197]. In 2014, pimavanserin is an antagonist at 5-HT2A-receptors entered the market in the USA as an antipsychotic drug and to treat Parkinson’s disease [198]. 
Interestingly, the producing company lists as contraindications irregular heartbeat. In some 
countries, ketanserin (a classical 5-HT2A-antagonist) has been used for many years to treat hyper-
tension. However, the antihypertensive effect is probably due to an additional α1-adrenoceptor antagonistic effect of ketanserin [2]. Moreover, its use has rapidly declined when it was sug-
gested to lead to deadly arrhythmias (ketanserin can make QT prolongation and thereby lead 
to torsade de pointes). The reason for this is that the K+ channel hERG (human ether-a-go-go-
related gene) is blocked by ketanserin (reviewed in [2]).
5-HT2C-receptors: A newer serotonergic drug is the 5-HT2C-agonist lorcaserin that was approved by the FDA in June 2012 in order to bring about weight loss by action in the CNS 
[198]. Lorcaserin was developed because older drugs for weight loss were withdrawn, in the 
past, from the market (e.g. fenfluramine) because they led to fibrosis (reviewed in Ref. [70]). 
Clearly, one can speculate that lorcaserin might also have agonistic properties at 5-HT2B-receptors and thus may have effects on valves. Initial studies did not detect an increased risk 
of lorcaserin for valvulopathies, however the incidence of headaches was increased versus 
placebo which may mean that lorcaserin can act agonistic on other 5-HT receptors [199] and 
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-receptors: Metoclopramide acts on many receptors but in this context the activation of 
5-HT
4
-receptors is important [200]. One has speculated that 5-HT
4
-receptor agonists might 
be useful to treat patients with sinus bradycardia, slowing of AV conduction, and autonomic 
dysfunction of the heart [201]. 5-HT
4
-receptor agonists are used in some countries to treat 
irritable bowel disease (e.g. prucalopride [202]), bladder dysfunction [203], and Morbus 
Alzheimer (e.g. [204]). However, early on a clinical study detected arrhythmias in ECG of 
healthy volunteers [205], which used the 5-HT
4
-receptor agonist prucalopride, and hence cau-
tion in its used is advised. The 5-HT
4
-receptor agonist (RS 67333) donecopride, in addition, 
inhibits the activity of acetylcholine esterases [206] and might be useful for the treatment of 
Morbus Alzheimer. However, this compound is expected to lead to arrhythmias in sensitive 




-receptor agonists have been 
developed to treat anxiety or chronic obstipation. 5-HT
4
-receptor antagonists have been sug-
gested for the treatment of supraventricular arrhythmias [159, 189] but were not successful 
due to side effects [106].
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